iKEY technology will be used to warn you of the likelihood of having Glaucoma.
Glaucoma is known as the SILENT THIEF. The optic nerve loses fibres and the patient loses eye sight BEFORE they become aware of it, because usually sight in one eye can compensate for sight loss in the same part of the visual field in the other eye.
Optic nerve rim thinning with pale central ‘cup’
iKEY technology uses computer vision to analyse then pattern of your own optic nerve head. As an optic nerve loses fibres, which carry images to your brain, the pattern of the nerve changes. iKEY will automatically comment on your own optic nerve pattern and provide an early warning system for protection of your optic nerve before any/further sight loss.
The only way to PREVENT silent loss of eyesight due to glaucoma at a global level, in particular amongst pre disposed African populations, is to screen people with photography and alert anyone with suspicious thinning of the optic nerve to get their eyes examined by a professional eye expert.
WHO has estimated that 4.5 million people are blind due to glaucoma
Glaucoma is the second leading cause of blindness and the leading cause of irreversible blindness worldwide.
It has been estimated that by 2020 there will be approximately 80 million people with glaucoma, an increase of about 20 million since 2010. Furthermore, it is thought that at present over 8 million people are bilaterally blind due to glaucoma, a figure that is set to rise to over 11 million by 2020 with the increasing prevalence, unless improved screening and effective treatment strategies are successful.
The term ‘glaucoma’ relates to a group of conditions that can be classified in a variety of ways, but all of which are characterised by optic nerve damage (often referred to as cupping) and visual field loss (often with an arcuate pattern of mid-peripheral loss), secondary to retinal ganglion cell damage and death. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG).
iKEY technology will be used to screen the global population to detect glaucoma susceptibility BEFORE the person notices vision loss.